https://adisinsight.springer.com/trials/700251593?error=cookies_not_supported&code=130e3d36-9fb3-460e-911a-28d35a6a1050
Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in...
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2024.1373375/full
Frontiers | Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in...
Objective To observe the efficacy and safety of pelvic floor magnetic stimulation (PFMS) combined with mirabegron in female patients with refractory overacti...
efficacy and safety
https://www.myrbetriq.com/
Overactive Bladder (OAB) Medication | Myrbetriq (mirabegron ER tablets)
Myrbetriq is an FDA-approved treatment for overactive bladder (OAB) with symptoms of urgency, frequency and leakage in adults. Learn about Myrbetriq.
overactive bladderoabmedicationmyrbetriqmirabegron
https://www.ncbi.nlm.nih.gov/books/NBK538513/
Mirabegron - StatPearls - NCBI Bookshelf
Mirabegron is a medication used in the management of overactive bladder. It is in the sympathomimetic class of medications. It received approval from the US...
mirabegronncbibookshelf
https://adisinsight.springer.com/patents/800017376
Mirabegron - Astellas Pharma - AdisInsight
astellas pharmamirabegronadisinsight
https://www.businesswire.com/news/home/20240422114589/en/Zydus-launches-Mirabegron-Extended-Release-Tablets-in-the-US
Zydus launches Mirabegron Extended-Release Tablets in the US
Zydus Lifesciences Limited announces the launch of Mirabegron Extended-Release Tablets, 25 mg in the US market.
extended releasein thezyduslaunchesmirabegron
https://pharma.economictimes.indiatimes.com/tag/mirabegron
Mirabegron - Latest mirabegron , Information & Updates - Pharma -ETPharma
ETPharma.com brings latest mirabegron news, views and updates from all top sources for the Indian Pharma industry.
latest informationmirabegronupdatespharma